AbbVie Inc. (ABBV) Earnings Yield: 0.90%
Is AbbVie Inc.’s earnings yield high or low?
AbbVie Inc.'s earnings yield of 0.90% is 65% below its 5-year average of 2.60%, near the low end of its 5-year range (0.56%–5.27%).
As of Thursday, June 11, 2026. 3.05% below its 12-month average of 0.93%.
ABBV Earnings Yield Chart
ABBV Average Earnings Yield Chart
ABBV Current vs Average Earnings Yield Chart
ABBV Earnings Yield Metrics
EARNINGS YIELD
0.90%
EARNINGS YIELD AVG TTM
0.93%
EARNINGS YIELD AVG 3Y
1.66%
EARNINGS YIELD AVG 5Y
2.60%
EARNINGS YIELD AVG 10Y
3.65%
EARNINGS YIELD AVG 15Y
3.95%
EARNINGS YIELD AVG 20Y
3.95%
CURRENT VS TTM AVG
-3.05%
CURRENT VS 3Y AVG
-45.63%
CURRENT VS 5Y AVG
-65.42%
CURRENT VS 10Y AVG
-75.32%
CURRENT VS 15Y AVG
-77.24%
CURRENT VS 20Y AVG
-77.24%
ABBV Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $399.86B | 0.90% | 0.93% | 1.66% | 2.60% |
| UnitedHealth Group Incorporated (UNH) | $369.16B | 3.26% | 6.03% | 4.62% | 4.30% |
| Merck & Co., Inc. (MRK) | $298.23B | 2.94% | 6.88% | 4.56% | 4.76% |
| Johnson & Johnson (JNJ) | $577.73B | 3.60% | 4.90% | 5.96% | 5.19% |
| Amgen Inc. (AMGN) | $188.37B | 4.26% | 4.01% | 3.83% | 4.18% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 3.83% | 3.47% | 3.14% | 3.26% |
| Gilead Sciences, Inc. (GILD) | $156.35B | 6.04% | 4.73% | 3.68% | 4.37% |
| Abbott Laboratories (ABT) | $155.75B | 4.01% | 5.49% | 4.05% | 3.87% |
| Pfizer Inc. (PFE) | $149.61B | 4.99% | 6.28% | 6.38% | 7.46% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 2.00% | 1.54% | 1.36% | 1.43% |
Earnings Yield vs P/E Ratio
Earnings Yield
0.90%
EPS ÷ Price
P/E Ratio
110.9
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
AbbVie Inc. Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Earnings Yield FAQ
- What is the earnings yield for AbbVie Inc. (ABBV)?
- The earnings yield for ABBV stock is 0.90%.
- Is AbbVie Inc.'s earnings yield high or low?
- AbbVie Inc.'s earnings yield of 0.90% is 65% below its 5-year average of 2.60%, near the low end of its 5-year range (0.56%–5.27%).
- What is the TTM average earnings yield for AbbVie Inc. (ABBV)?
- The TTM average earnings yield for ABBV stock is 0.93%.
- What is the 3Y average earnings yield for AbbVie Inc. (ABBV)?
- The 3Y average earnings yield for ABBV stock is 1.66%.
- What is the 5Y average earnings yield for AbbVie Inc. (ABBV)?
- The 5Y average earnings yield for ABBV stock is 2.60%.
- What is the 10Y average earnings yield for AbbVie Inc. (ABBV)?
- The 10Y average earnings yield for ABBV stock is 3.65%.
- What is the 15Y average earnings yield for AbbVie Inc. (ABBV)?
- The 15Y average earnings yield for ABBV stock is 3.95%.
- What is the 20Y average earnings yield for AbbVie Inc. (ABBV)?
- The 20Y average earnings yield for ABBV stock is 3.95%.
AbbVie Inc. Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2026-06-11 | 0.90% |
| 2026-06-10 | 0.91% |
| 2026-06-09 | 0.90% |
| 2026-06-08 | 0.91% |
| 2026-06-05 | 0.90% |
| 2026-06-04 | 0.91% |
| 2026-06-03 | 0.94% |
| 2026-06-02 | 0.95% |
| 2026-06-01 | 0.96% |
| 2026-05-29 | 0.94% |
| 2026-05-28 | 0.93% |
| 2026-05-27 | 0.95% |
| 2026-05-26 | 0.96% |
| 2026-05-22 | 0.95% |
| 2026-05-21 | 0.95% |
| 2026-05-20 | 0.96% |
| 2026-05-19 | 0.95% |
| 2026-05-18 | 0.97% |
| 2026-05-15 | 0.97% |
| 2026-05-14 | 0.97% |
| 2026-05-13 | 0.98% |
| 2026-05-12 | 0.98% |
| 2026-05-11 | 1.01% |
| 2026-05-08 | 1.01% |
| 2026-05-07 | 1.17% |
| 2026-05-06 | 1.16% |
| 2026-05-05 | 1.15% |
| 2026-05-04 | 1.14% |
| 2026-05-01 | 1.15% |
| 2026-04-30 | 1.12% |
| 2026-04-29 | 1.16% |
| 2026-04-28 | 1.20% |
| 2026-04-27 | 1.20% |
| 2026-04-24 | 1.19% |
| 2026-04-23 | 1.18% |
| 2026-04-22 | 1.18% |
| 2026-04-21 | 1.16% |
| 2026-04-20 | 1.16% |
| 2026-04-17 | 1.14% |
| 2026-04-16 | 1.13% |
| 2026-04-15 | 1.14% |
| 2026-04-14 | 1.13% |
| 2026-04-13 | 1.15% |
| 2026-04-10 | 1.14% |
| 2026-04-09 | 1.12% |
| 2026-04-08 | 1.12% |
| 2026-04-07 | 1.15% |
| 2026-04-06 | 1.15% |
| 2026-04-02 | 1.13% |
| 2026-04-01 | 1.10% |
| 2026-03-31 | 1.09% |
| 2026-03-30 | 1.11% |
| 2026-03-27 | 1.13% |
| 2026-03-26 | 1.12% |
| 2026-03-25 | 1.14% |
| 2026-03-24 | 1.15% |
| 2026-03-23 | 1.16% |
| 2026-03-20 | 1.16% |
| 2026-03-19 | 1.15% |
| 2026-03-18 | 1.14% |
| 2026-03-17 | 1.08% |
| 2026-03-16 | 1.07% |
| 2026-03-13 | 1.08% |
| 2026-03-12 | 1.05% |
| 2026-03-11 | 1.04% |
| 2026-03-10 | 1.04% |
| 2026-03-09 | 1.04% |
| 2026-03-06 | 1.03% |
| 2026-03-05 | 1.02% |
| 2026-03-04 | 1.00% |
| 2026-03-03 | 1.01% |
| 2026-03-02 | 1.01% |
| 2026-02-27 | 1.02% |
| 2026-02-26 | 1.05% |
| 2026-02-25 | 1.04% |
| 2026-02-24 | 1.04% |
| 2026-02-23 | 1.03% |
| 2026-02-20 | 1.05% |
| 2026-02-19 | 0.59% |
| 2026-02-18 | 0.58% |
| 2026-02-17 | 0.57% |
| 2026-02-13 | 0.58% |
| 2026-02-12 | 0.59% |
| 2026-02-11 | 0.60% |
| 2026-02-10 | 0.60% |
| 2026-02-09 | 0.60% |
| 2026-02-06 | 0.60% |
| 2026-02-05 | 0.61% |
| 2026-02-04 | 0.61% |
| 2026-02-03 | 0.59% |
| 2026-02-02 | 0.59% |
| 2026-01-30 | 0.60% |
| 2026-01-29 | 0.60% |
| 2026-01-28 | 0.61% |
| 2026-01-27 | 0.59% |
| 2026-01-26 | 0.60% |
| 2026-01-23 | 0.61% |
| 2026-01-22 | 0.61% |
| 2026-01-21 | 0.62% |
| 2026-01-20 | 0.62% |
| 2026-01-16 | 0.62% |
| 2026-01-15 | 0.61% |
| 2026-01-14 | 0.60% |
| 2026-01-13 | 0.60% |
| 2026-01-12 | 0.60% |
| 2026-01-09 | 0.60% |
| 2026-01-08 | 0.59% |
| 2026-01-07 | 0.57% |
| 2026-01-06 | 0.59% |
| 2026-01-05 | 0.60% |
| 2026-01-02 | 0.58% |
| 2025-12-31 | 0.58% |
| 2025-12-30 | 0.58% |
| 2025-12-29 | 0.58% |
| 2025-12-26 | 0.58% |
| 2025-12-24 | 0.58% |
| 2025-12-23 | 0.58% |
| 2025-12-22 | 0.58% |
| 2025-12-19 | 0.59% |
| 2025-12-18 | 0.60% |
| 2025-12-17 | 0.59% |
| 2025-12-16 | 0.60% |
| 2025-12-15 | 0.59% |
| 2025-12-12 | 0.60% |
| 2025-12-11 | 0.59% |
| 2025-12-10 | 0.59% |
| 2025-12-09 | 0.60% |
| 2025-12-08 | 0.60% |
| 2025-12-05 | 0.59% |
| 2025-12-04 | 0.58% |
| 2025-12-03 | 0.58% |
| 2025-12-02 | 0.59% |
| 2025-12-01 | 0.59% |
| 2025-11-28 | 0.58% |
| 2025-11-26 | 0.58% |
| 2025-11-25 | 0.57% |
| 2025-11-24 | 0.58% |
| 2025-11-21 | 0.56% |
| 2025-11-20 | 0.58% |
| 2025-11-19 | 0.57% |
| 2025-11-18 | 0.57% |
| 2025-11-17 | 0.57% |
| 2025-11-14 | 0.57% |
| 2025-11-13 | 0.57% |
| 2025-11-12 | 0.57% |
| 2025-11-11 | 0.59% |
| 2025-11-10 | 0.61% |
| 2025-11-07 | 0.61% |
| 2025-11-06 | 0.61% |
| 2025-11-05 | 0.61% |
| 2025-11-04 | 0.62% |
| 2025-11-03 | 1.00% |
| 2025-10-31 | 0.97% |
| 2025-10-30 | 0.93% |
| 2025-10-29 | 0.94% |
| 2025-10-28 | 0.93% |
| 2025-10-27 | 0.93% |
| 2025-10-24 | 0.93% |
| 2025-10-23 | 0.93% |
| 2025-10-22 | 0.92% |
| 2025-10-21 | 0.91% |
| 2025-10-20 | 0.91% |
| 2025-10-17 | 0.92% |
| 2025-10-16 | 0.93% |
| 2025-10-15 | 0.93% |
| 2025-10-14 | 0.92% |
| 2025-10-13 | 0.92% |
| 2025-10-10 | 0.92% |
| 2025-10-09 | 0.92% |
| 2025-10-08 | 0.91% |
| 2025-10-07 | 0.91% |
| 2025-10-06 | 0.92% |
| 2025-10-03 | 0.90% |
| 2025-10-02 | 0.89% |
| 2025-10-01 | 0.86% |
| 2025-09-30 | 0.91% |
| 2025-09-29 | 0.95% |
| 2025-09-26 | 0.96% |
| 2025-09-25 | 0.97% |
| 2025-09-24 | 0.96% |
| 2025-09-23 | 0.95% |
| 2025-09-22 | 0.95% |
| 2025-09-19 | 0.95% |
| 2025-09-18 | 0.95% |
| 2025-09-17 | 0.96% |
| 2025-09-16 | 0.98% |
| 2025-09-15 | 0.97% |
| 2025-09-12 | 0.97% |
| 2025-09-11 | 0.96% |
| 2025-09-10 | 1.00% |
| 2025-09-09 | 1.00% |
| 2025-09-08 | 1.01% |
| 2025-09-05 | 0.99% |
| 2025-09-04 | 0.99% |
| 2025-09-03 | 1.00% |
| 2025-09-02 | 1.00% |
| 2025-08-29 | 1.00% |
| 2025-08-28 | 1.02% |
| 2025-08-27 | 1.02% |
| 2025-08-26 | 1.01% |
| 2025-08-25 | 1.02% |
| 2025-08-22 | 1.00% |
| 2025-08-21 | 1.01% |
| 2025-08-20 | 1.01% |
| 2025-08-19 | 1.02% |
| 2025-08-18 | 1.02% |
| 2025-08-15 | 1.02% |
| 2025-08-14 | 1.03% |
| 2025-08-13 | 1.05% |
| 2025-08-12 | 1.06% |
| 2025-08-11 | 1.06% |
| 2025-08-08 | 1.07% |
| 2025-08-07 | 1.06% |
| 2025-08-06 | 1.08% |
| 2025-08-05 | 1.06% |
| 2025-08-04 | 1.07% |
| 2025-08-01 | 1.20% |
| 2025-07-31 | 1.24% |
| 2025-07-30 | 1.24% |
| 2025-07-29 | 1.23% |
| 2025-07-28 | 1.25% |
| 2025-07-25 | 1.24% |
| 2025-07-24 | 1.23% |
| 2025-07-23 | 1.23% |
| 2025-07-22 | 1.26% |
| 2025-07-21 | 1.27% |
| 2025-07-18 | 1.24% |
| 2025-07-17 | 1.23% |
| 2025-07-16 | 1.23% |
| 2025-07-15 | 1.26% |
| 2025-07-14 | 1.23% |
| 2025-07-11 | 1.22% |
| 2025-07-10 | 1.21% |
| 2025-07-09 | 1.23% |
| 2025-07-08 | 1.24% |
| 2025-07-07 | 1.25% |
| 2025-07-03 | 1.24% |
| 2025-07-02 | 1.23% |
| 2025-07-01 | 1.24% |
| 2025-06-30 | 1.27% |
| 2025-06-27 | 1.29% |
| 2025-06-26 | 1.26% |
| 2025-06-25 | 1.27% |
| 2025-06-24 | 1.27% |
| 2025-06-23 | 1.28% |
| 2025-06-20 | 1.27% |
| 2025-06-18 | 1.27% |
| 2025-06-17 | 1.27% |
| 2025-06-16 | 1.23% |
| 2025-06-13 | 1.23% |
| 2025-06-12 | 1.22% |
| 2025-06-11 | 1.23% |
| 2025-06-10 | 1.24% |
| 2025-06-09 | 1.24% |
| 2025-06-06 | 1.24% |
| 2025-06-05 | 1.25% |
| 2025-06-04 | 1.26% |
| 2025-06-03 | 1.26% |
| 2025-06-02 | 1.26% |
| 2025-05-30 | 1.26% |
Showing the most recent 260 of 3,396 data points. The chart above shows the full history.
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael